Dr Colin Murdoch obtained his doctorate under the supervision of Prof Ajay Shah through the British Heart Foundation 4-year Ph.D program at the BHF Cardiovascular Centre of Excellence, King’s College London. He investigated the “Influence of endothelial NADPH oxidase on cardiac fibrosis and remodelling in the hypertensive heart.” utilising murine cardiovascular techniques such as pressure-volume loops, echocardiography and telemetry.
Dr Murdoch conducted post-doctoral training with Richard Cohen and Reiko Matsui at the Whitaker Cardiovascular Institute, Boston University investigating redox signalling in neovascularisation in type-2 diabetes. He moved back to the UK and was awarded a highly competitive Marie Skłodowska-Curie International Incoming Fellowship to transfer in vivo cardiovascular phenotyping techniques to Aston Medical School working in Prof Asif Ahmed’s laboratory.
Previously he worked as a functional pharmacologist for 5-years at Asterand Biosceince after gaining his honours degree in Pharmacology with Industrial Experience at University of Edinburgh.
Dr Murdoch joined the faculty at School of Medicine, University of Dundee in March 2018. His research focuses on the pathophysiological role of redox signalling in cardiovascular disease including preeclampsia and peripheral artery disease. Dr Murdoch is the project coordinator for EU Horizon2020 Innovative training network, iPLACENTA. Involving a collaborative training network between 11 institutes across Europe.
Dr Murdoch’s research aims to understand the pathophysiological role of redox signalling in cardiovascular disease, focusing on signalling in the endothelium. Currently he is investigating how oxidative post-translational modification of thiols contribute to the preeclampsia phenotype.
Dr Murdoch is the coordinator of iPLACENTA, a €3.9 million Horizon 2020 innovative training network (ITN). A multi-disciplinary network of 11 European partners delivering post-graduate training for 15 Early stage researchers (ESRs/Ph,D). The principal research aim of iPLACENTA is to improve the ability to study, model and visualise the placenta to enhance investigation and prognosis of complicated pregnancies such as preeclampsia and intrauterine growth restriction. Integrating organ-chip technology and mathematical modelling, with innovation in visualising and assessing placenta health in the clinic and pre-clinical models. The research will interconnect to unlock the complexity of placental disease, providing mechanistic clues for complex diseases, new ways to model placenta function, validate novel clinical diagnostic tools and characterise in vivo pre-clinical models. The PhD training programme aims to equip the ESRs with the necessary skills to meet the challenges of cutting-edge translational research alongside topics such as OpenScience, entrepreneurship, project management and business skills. See www.iplacenta.eu
'Cardiac fibrosis can be attenuated by blocking the activity of transglutaminase 2 using a selective small-molecule inhibitor' Cell Death and Disease, vol. 9, no. 6, pp. 613.
'Therapeutic Angiogenesis of Chinese Herbal Medicines in Ischemic Heart Disease: A Review' Frontiers in Pharmacology, vol. 9.
'Vascular endothelial growth factor signaling requires glycine to promote angiogenesis' Scientific Reports, vol. 7, no. 1, pp. 14749.
'Differential regulation of ischemic limb vascularization and tumor growth by endothelial glutaredoxin-1' Free Radical Biology and Medicine, vol. 112, no. 1, pp. 38-39.
'Redox regulation of ischemic limb neovascularization - What we have learned from animal studies' Redox Biology, vol. 12, pp. 1011-1019.
'Protein thiol modifications in the development of the 'preeclampsia phenotype'' Free Radical Biology and Medicine, vol. 108, pp. S51-S51.
'The impact of environmental factors in influencing epigenetics related to oxidative states in the cardiovascular system' Oxidative Medicine and Cellular Longevity, vol. 2017, 2712751, pp. 1-18.
'Distinct regulatory effects of myeloid cell and endothelial cell Nox2 on blood pressure' Circulation, vol. 135, no. 22, pp. 2163-2177.
'Heterodimerisation between VEGFR-1 and VEGFR-2 and not the homodimers of VEGFR-1 inhibit VEGFR-2 activity' Vascular Pharmacology, vol. 88, pp. 11-20.
'Cell-specific effects of Nox2 on the acute and chronic response to myocardial infarction' Journal of Molecular and Cellular Cardiology, vol. 98, pp. 11-17.
'Endothelial cell redox regulation of ischemic angiogenesis' Journal of Cardiovascular Pharmacology, vol. 67, no. 6, pp. 458-464.
'Glutathione adducts induced by ischemia and deletion of glutaredoxin-1 stabilize HIF-1α and improve limb revascularization' Proceedings of the National Academy of Sciences, vol. 113, no. 21, pp. 6011-6016.
'Development of potent and selective tissue transglutaminase inhibitors' Chemistry & Biology, vol. 22, no. 10, pp. 1347-1361.
'TG2: a credible therapeutic target in fibrotic diseasedue to its multifunctional roles' Amino Acids, vol. 47, no. 8, pp. 1629.
'Glutaredoxin-1 Is up-regulated in preeclampsia and increases soluble Flt-1 expression' pp. 203A-204A.
'Regulation of neovascularization by S-glutathionylation via the Wnt5a/s Flt-1 pathway' Biochemical Society Transactions, vol. 42, no. 6, pp. 1665-1670.
'Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through proinflammatory effects and endothelial-mesenchymal transition' Journal of the American College of Cardiology, vol. 63, no. 24, pp. 2734-2741.
'Influence of Egr-1 in cardiac tissue-derived mesenchymal stem cells in response to glucose variations' Bio Med Research International, vol. 2014, 254793, pp. 1-11.
'Glutaredoxin-1 up-regulation induces soluble vascular endothelial growth factor receptor 1, attenuating post-ischemia limb revascularization' Journal of Biological Chemistry, vol. 289, no. 12, pp. 8633-8644.
'Erratum to: Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction (Basic Res Cardiol (2011) 106, (527-538) DOI:10.1007/s00395-011-0179-7)' Basic Research in Cardiology, vol. 109, no. 3, 410.
'Stem cell therapies for ischemic cardiovascular diseases' Recent Patents on Regenerative Medicine, vol. 4, no. 3, pp. 149-167.
'Gene network and proteomic analyses of cardiac responses to pathological and physiological stress' Circulation: Cardiovascular Genetics, vol. 6, no. 6, pp. 588-597.
'Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction' Basic Research in Cardiology, vol. 106, no. 4, pp. 527-538.
'Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo' Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 31, no. 6, pp. 1368-1376.
'Constitutive glycogen synthase kinase-3α/β activity protects against chronic β-adrenergic remodelling of the heart' Cardiovascular Research, vol. 87, no. 3, pp. 494-503.
'Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis' Journal of Vascular Surgery, vol. 50, no. 5, pp. 1127-1134.
'NADPH oxidase signaling and cardiac myocyte function' Journal of Molecular and Cellular Cardiology, vol. 47, no. 1, pp. 15-22.
'Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice' European Journal of Heart Failure, vol. 11, no. 6, pp. 533-541.
'Involvement of NADPH oxidases in cardiac remodelling and heart failure' Journal of the American Society of Nephrology, vol. 27, no. 6, pp. 649-660.
'NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure' Cardiovascular Research, vol. 71, no. 2, pp. 208-215.
'NADPH oxidase and heart failure' Current Opinion in Pharmacology, vol. 6, no. 2, pp. 148-153.
'EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries' British Journal of Pharmacology, vol. 141, no. 4, pp. 580-585.